LTGO.US Latigo Biotherapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
13.11 USD
Close of Nov 15, 2026
10.24 25.93
Market cap
USD 869M
P/E
-
P/B
2.22x
ROE
-23.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LTGO.US undervalued?

Graham number

The Graham number of Latigo Biotherapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Latigo Biotherapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Latigo Biotherapeutics, Inc. Common Stock yet.

Latigo Biotherapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Latigo Biotherapeutics, Inc. Common Stock

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment…

Full company profile